Screener
Gyre Therapeutics, Inc. GYRE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s cash & equivalents?
- Gyre Therapeutics, Inc. (GYRE) reported cash & equivalents of $43.29M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Gyre Therapeutics, Inc.'s cash & equivalents increased by 18.6% year-over-year, from $36.49M to $43.29M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s cash & equivalents has grown at a 10.1% compound annual growth rate (CAGR), from $30.36M to $49.19M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Gyre Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude